Latest News

 Filter by Provider

PFE earnings call for the period ending December 31, 2024.

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Pfizer Inc. (NYSEPFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.

Wedbush’s Scott Devitt said Alphabet will unlikely materially outperform advertising revenue growth expectations in the fourth quarter and 2025 due to forex headwinds and more challenging comps.

BofA Securities analyst Vivek Arya maintained a Buy rating on Nvidia Corp (NASDAQNVDA) with a price target of $190.

Under the contract terms, the company will deliver space-based imagery services to international customers.

Tuesday afternoon Dave traded at nearly 98, up more than 7% for the day. Look for the stock to break out in volume at least 40% above average.

PJT Partners reported exceptional results for the fourth quarter.

Global corn markets recovered on Monday as free trade with Mexico and Canada resumed for the next 30 days.

Shares of SoundHound AI are trading within a range. Some traders will get involved if the stock breaks out or breaks down.

Piper Sandler analyst Michael Lavery upgraded Tyson Foods to Neutral, maintaining a $58 price target. The company exceeded expectations with a 9.1% Chicken EBIT margin in Q1, the highest since FY2018.

Analyst reiterates Buy rating and $265 price target for Apple based on strong App Store revenues and diversification in app categories.

The power solutions provider’s fourth-quarter revenue of $8.45 billion beat the average analysts’ estimate of $8.09 billion, according to FinChat data.

ETFs are becoming popular for investors looking for exposure to high-growth stocks without single-stock risk. Palantir's strong Q4 earnings make it a top holding in 4 ETFs, including ARKK, SHLD, and FPX.

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

There's no good reason to buy this stock.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Nintendo's Q3 revenue decreased to 432.92 billion Japanese yen, with EPS at 110.40 Japanese yen. It sold 4.82 million Nintendo Switch units and lowered sales forecasts for fiscal 2025.

The midstream energy giant reported solid fourth-quarter results, with notable advances in revenue and operational metrics.

A look at the key earnings estimates for Disney's first-quarter financial results and items investors and analysts will be closely watching.

President Donald Trump's executive order to create a U.S. Sovereign Wealth Fund (SWF) has triggered debates over its structure, funding and potential investments.

The firm said it had begun the search for Hurlston’s replacement. In the meantime, CFO Ken Rizvi will serve as interim CEO.

Goldman Sachs analyst Bonnie Herzog reiterated a Buy rating on the shares of PepsiCo with a price forecast of $189.00.